Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Authors
Keywords
-
Journal
Nature Communications
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-13
DOI
10.1038/s41467-023-35815-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
- (2022) Wilfredo F. Garcia-Beltran et al. CELL
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
- (2022) Hung Fu Tseng et al. NATURE MEDICINE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
- (2022) Daichi Yamasoba et al. CELL
- Letter to the editor: Epidemiology of the SARS-CoV-2 variant Omicron BA.2 – vigilance needed
- (2022) Jing Huang et al. Eurosurveillance
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
- (2022) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization
- (2022) Daniel R. Feikin et al. VACCINE
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
- (2022) Hiam Chemaitelly et al. Nature Communications
- Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
- (2022) Adam S Lauring et al. BMJ-British Medical Journal
- Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
- (2022) Sara Y Tartof et al. Lancet Respiratory Medicine
- Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022
- (2022) Kristie E.N. Clarke et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
- (2022) Qian Wang et al. NATURE
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
- (2022) Houriiyah Tegally et al. NATURE MEDICINE
- Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
- (2022) Panke Qu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
- (2022) Nicole P. Hachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
- (2022) Heba N. Altarawneh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
- (2022) Khadija Khan et al. Nature Communications
- Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
- (2022) Ruth Link-Gelles et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Long-term Protection Associated With COVID-19 Vaccination and Prior Infection
- (2022) Mark W. Tenforde et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
- (2022) Sara Y Tartof et al. LANCET INFECTIOUS DISEASES
- Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
- (2022) Panke Qu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
- (2022) João Malato et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
- (2022) Julia Stowe et al. Nature Communications
- Durable spike-specific T-cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination
- (2022) Yacine Maringer et al. Science Immunology
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- (2021) Shirley Collie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
- (2021) Katia J Bruxvoort et al. BMJ-British Medical Journal
- Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index
- (2017) Dae Hyun Kim et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
- (2011) H. Quan et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started